Middle East Conflict Disrupts Pharmaceutical Supply Chains, Potential for Rising Drug Costs

The escalating conflict in the Middle East is creating ripples across global logistics, with potential consequences for the pharmaceutical industry and, drug prices. While widespread medicine shortages are not currently anticipated in the United States, disruptions to key transportation corridors are forcing pharmaceutical companies to adapt and reroute shipments, adding to costs that could be passed on to consumers.

Impact on Critical Logistics Corridors

The war has significantly disrupted two vital logistics routes: the Strait of Hormuz and major Gulf air hubs. As of March 16, 2026, commercial activity through the Strait of Hormuz was 90% below pre-war levels. Between February 28 and March 3, 2026, global air-cargo capacity in the Gulf region dropped by 79%, leading to a 22% reduction worldwide Think Global Health.

Regional Impact and Global Repercussions

The immediate impact is most pronounced in the Middle East, which accounts for only a modest fraction of global pharmaceutical production – 0.3% of the world’s medicines and 0.6% of active pharmaceutical ingredients Think Global Health. However, the disruption of shipping and air routes is affecting manufacturers, particularly those in India and the European Union, who rely on these pathways.

Specifically, shipments of medicines for clinical trials and ultra-cold chain shipments carrying biologics are particularly vulnerable Fierce Pharma. Rising oil prices, a consequence of the conflict, are also impacting transportation and energy costs across the entire manufacturing system Fierce Pharma.

Rerouting Strategies and Cost Increases

Pharmaceutical companies are proactively seeking alternative routes to maintain uninterrupted delivery. These strategies include utilizing land routes to truck cargo between airports in the Gulf Cooperation Council (GCC) region and diverting air cargo to China or Singapore Think Global Health.

These rerouting efforts come at a cost. Experts warn that consumers could see drug costs affected within four to six weeks due to increased Indian air-cargo rates Think Global Health. The increased expenses will likely burden pharmaceutical export-dependent economies as well.

Government Monitoring and Future Outlook

Governments are closely monitoring the situation. The federal government is actively tracking medicines supply chains to mitigate potential disruptions ABC News.

While immediate, widespread shortages are unlikely due to existing inventory buffers and continued Suez Canal shipping, the conflict highlights the necessitate for diversification and streamlining of pharmaceutical supply chains to build long-term resilience.